Transcenta Holding, a global clinical-stage biopharmaceutical company, has announced a strategic collaboration and non-exclusive licensing deal with EirGenix, a leading biopharmaceutical development and manufacturing company. 

Under the agreement, Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform. The platform includes continuous perfusion and integrated hybrid continuous purification technologies, along with comprehensive process documentation, know-how, and regulatory support packages.  

Transcenta stands to receive substantial upfront and milestone payments, plus future royalties linked to commercial use of the technology. 

The HiCB platform is designed to enhance efficiency, improve process control and product consistency, and significantly lower costs compared to traditional fed-batch manufacturing. The technology aims to broaden global patient access to high-quality, affordable biologics. 

EirGenix will integrate Transcenta’s HiCB platform into its biologics development programs and CDMO manufacturing operations, supporting clients seeking intensified and continuous manufacturing solutions. 

“We are pleased to share our HiCB platform, a result of Transcenta’s leadership in highly intensified continuous bioprocessing, with partners who share our vision of transforming biologics manufacturing,” said Dr Xueming Qian, Chairman and CEO of Transcenta.  

“By enabling others to implement HiCB, we can collectively advance affordability of and global access to innovative biologics. The proceeds from this and future collaborations will be reinvested to further strengthen our technology platform and advance our R&D pipeline to deliver next-generation, best in class therapeutics.” 

“This collaboration represents a win–win partnership that combines Transcenta’s innovation in continuous biomanufacturing and EirGenix’s proven bioprocessing and CDMO expertise,” said Dr LC Liu, Chairman and President of EirGenix. “Together, we aim to redefine how biologics are made—more efficiently, sustainably, and at lower cost—to reach more patients worldwide.”